Posted: 6 April 2023
Respiratory imaging technology company 4DMedical Limited today announces a significant milestone in its commercialisation journey with the signing of a five-year contract with the University of Miami to provide XV LVAS® (X-ray Velocimetry Lung Ventilation Analysis Software) ventilation reports.
Expanding on existing relationship
4DMedical has established a strong relationship with the University of Miami where joint clinical research is underway demonstrating the clinical value of XV Technology® across a range of indications, including Chronic Obstructive Pulmonary Disease (COPD). COPD represents a significant worldwide health problem, and according to the World Health Organisation (WHO) it is the third leading cause of death worldwide. The Australian Lung Foundation states that around 1 in 7 Australians over 40 have COPD, and around half of these don’t know that they have the condition. However, if diagnosed early enough (prior to the occurrence of structural changes in the lungs), COPD is a treatable condition.
Researchers at the University of Miami have presented findings from these trials at key international conferences, noting the clinical insights delivered using 4DMedical’s game changing technology. In addition, University of Miami researchers were integrally involved in the recently completed COPD study at Johns Hopkins. This study was initially presented in May 2022 at the American Thoracic Society conference. Key findings of the published study included that:
• XV Technology® derived metrics correspond with COPD disease severity;
• Pathophysiological insights have application in both clinical and research settings; and
• XV LVAS® scans visualise and quantify regional ventilation defects, which is critical to the optimisation of treatment therapies.
Contract framework
The agreement with the University of Miami sets out a framework for further expansion of 4DMedical’s XV Technology® into the US market. Under the terms of the contract, 4DMedical will deploy XV Technology® at the University of Miami, enabling patient data to be processed on demand.
Importantly, this agreement includes minimum annual fees and represents a significant milestone in the commercialisation strategy of the Company in the US, validating the efficacy and utility of XV Technology®.
University of Miami Chief of Pulmonary and Sleep Medicine, Professor Naresh Punjabi, said:
We have had a long-standing relationship with the team at 4DMedical. Over that time, we have gained invaluable expertise in applying XV Technology® across various use cases and patient populations. We believe XV Technology® holds enormous potential to enhance clinical outcomes. I’m thrilled to be at the forefront of this ground-breaking technology and believe that XV LVAS® has the potential to revolutionize the way we diagnose and manage respiratory conditions.
4DMedical MD/CEO and Founder Andreas Fouras said:
Today’s announcement of our first US SaaS contract reflects the attainment of a key milestone in the Company’s commercialisation journey. Furthermore, the fact this milestone was completed with our clinical trial partners at the University of Miami, who have developed such an extensive understanding of XV Technology®, is especially satisfying.
The Company continues to go from strength to strength as commercialisation accelerates. I am excited by recent progress both in Australia and the USA, and I look forward to providing further positive updates over the coming weeks and months.
